Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study (Q38013498)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 May 2012

Language	Label	Description	Also known as
English	Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study	scientific article published on 24 May 2012

Statements

scholarly article

1 reference

27 August 2017

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study (English)

1 reference

27 August 2017

uterine carcinosarcoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Angeles Alvarez Secord

3

object named as

Angeles Alvarez Secord

1 reference

27 August 2017

Carol Aghajanian

1

object named as

Carol Aghajanian

1 reference

27 August 2017

author name string

Michael W Sill

2

1 reference

27 August 2017

Matthew A Powell

4

1 reference

27 August 2017

Margaret Steinhoff

5

1 reference

27 August 2017

language of work or name

0 references

publication date

24 May 2012

1 reference

27 August 2017

Gynecologic Oncology

1 reference

27 August 2017

126

1 reference

27 August 2017

424-427

1 reference

27 August 2017

3

1 reference

27 August 2017

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

FIGO staging for uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Letter: Creatinine clearance: bedside estimate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.05.024

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.05.024

1 reference

27 August 2017

1 reference

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38013498&oldid=2098706728"